Scientific Opinion on the substantiation of health claims related to conjugated linoleic acid (CLA) isomers and contribution to the maintenance or achievement of a normal body weight (ID 686, 726, 1516, 1518, 2892, 3165), increase in lean body mass (ID 498, 731), increase in insulin sensitivity (ID 1517), protection of DNA, proteins and lipids from oxidative damage (ID 564, 1937), and contribution to immune defences by stimulation of production of protective antibodies in response to vaccination (ID 687, 1519) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
Meta data
Keywords
Conjugated linoleic acid (CLA), isomers c9, t11 and t10, c12, body weight, lean body mass, insulin sensitivity, immune defences, pro-inflammatory, anti-inflammatory cytokines, health claims
On request from
European Commission
Question Number
EFSA-Q-2008-1285
EFSA-Q-2008-1351
EFSA-Q-2008-1473
EFSA-Q-2008-1513
EFSA-Q-2008-2253
EFSA-Q-2008-2254
EFSA-Q-2008-2255
EFSA-Q-2008-2670
EFSA-Q-2008-3625
EFSA-Q-2008-3897
EFSA-Q-2008-1518
EFSA-Q-2008-1474
EFSA-Q-2008-2256
Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Contact
Abstract
No abstract available
© European Food Safety Authority, 2010